About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, Mariona Morell Daniel Funding agency: Solving Kids’ Cancer Funding: 131766.91 Reference: SKC/AEFRM/2020/MORENO Duration: 02/11/2020 - 01/11/2023
IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, BEACON-BIO: deep biological characterisation and development of biomarkers for relapsed neuroblastoma Funding agency: European Science Foundation Funding: 104500 Reference: BEACON-BIO_FKC_2021 Duration: 01/01/2022 - 30/09/2025
IP: Josep Roma Castanyer Collaborators: Soledad Gallego Melcón, Guillem Pons Barcons, Constantino Sábado Álvarez, Raquel Hladun Alvaro, Patricia Zarzosa Martinez Funding agency: Instituto de Salud Carlos III Funding: 122815 Reference: PI21/00640 Duration: 01/01/2022 - 31/12/2025
IP: Lucas Moreno Martín-Retortillo Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Lorena Valero Arrese, Mariona Morell Daniel Funding agency: Instituto de Salud Carlos III Funding: 214170 Reference: PI21/01661 Duration: 01/01/2022 - 30/06/2026
The integration of Patient-Reported Outcome Measures (PROMs) will make it possible to incorporate patients' experiences and quality of life into research on sickle cell disease and other rare anaemias.
The Scientific Coordinator of ERN-EuroBloodNet will lead for one year the group that defines the common strategy of the European Reference Networks to improve care for rare and complex diseases.
Vall d’Hebron participates as a reference centre in Spain for early-phase clinical trials and coordinates the national ReALLNet network, promoting research into relapsed acute lymphoblastic leukemia.
